GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Shiller PE Ratio

Antibe Therapeutics (TSX:ATE) Shiller PE Ratio : (As of May. 23, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Antibe Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Antibe Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Shiller PE Ratio Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Antibe Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Antibe Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antibe Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Shiller PE Ratio falls into.



Antibe Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Antibe Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Antibe Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.08/125.0724*125.0724
=-0.080

Current CPI (Dec. 2023) = 125.0724.

Antibe Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.300 98.604 -0.381
201406 -0.400 99.473 -0.503
201409 -0.300 99.394 -0.378
201412 -0.200 98.367 -0.254
201503 -0.500 99.789 -0.627
201506 -0.100 100.500 -0.124
201509 -0.200 100.421 -0.249
201512 -0.100 99.947 -0.125
201603 -0.300 101.054 -0.371
201606 -0.100 102.002 -0.123
201609 -0.100 101.765 -0.123
201612 -0.200 101.449 -0.247
201703 -0.200 102.634 -0.244
201706 -0.200 103.029 -0.243
201709 -0.100 103.345 -0.121
201712 -0.100 103.345 -0.121
201803 -0.200 105.004 -0.238
201806 -0.100 105.557 -0.118
201809 -0.100 105.636 -0.118
201812 -0.200 105.399 -0.237
201903 -0.200 106.979 -0.234
201906 -0.100 107.690 -0.116
201909 -0.200 107.611 -0.232
201912 -0.150 107.769 -0.174
202003 -0.230 107.927 -0.267
202006 -0.160 108.401 -0.185
202009 -0.230 108.164 -0.266
202012 -0.170 108.559 -0.196
202103 -0.130 110.298 -0.147
202106 -0.130 111.720 -0.146
202109 -0.170 112.905 -0.188
202112 -0.090 113.774 -0.099
202203 -0.110 117.646 -0.117
202206 -0.100 120.806 -0.104
202209 -0.120 120.648 -0.124
202212 -0.080 120.964 -0.083
202303 -0.060 122.702 -0.061
202306 -0.110 124.203 -0.111
202309 -0.100 125.230 -0.100
202312 -0.080 125.072 -0.080

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Antibe Therapeutics  (TSX:ATE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Antibe Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibe Therapeutics (TSX:ATE) Business Description

Traded in Other Exchanges
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
Executives
Daniel Marcel Legault Senior Officer
Alain Wilson Senior Officer
John Lawrence Wallace Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines